Phantom Antibody from MyBioSource.com

Alternate nomenclature: Vitamin A transporter; Retinoic acid responsive protein, RBP4 Receptor Stra6. Stra6 gene encodes a membrane bound retinoic acid sensitive protein that facilitates the transport of vitamin A thru its soluble retinol binding protein complex. The transcription of Stra6 is directly regulated by the cellular levels of retinoic acid, which is a strong teratogen when exposed at elevated concentrations during early embryogenesis. The Stra 6 gene was studies in two human fetuses from consanguineous families with Matthew-Wood syndrome. These subjects exhibited severe microphthalmia, pulmonary agenesis, bilateral diaphragmatic eventration, duodenal stenosis, pancreatic malformations, and intrauterine growth retardation (1). In view of the increasing evidence that retinoic acid (RA) is a crucial signaling molecule during vertebrate development, several studies were initiated to systematically isolate the genes whose expression is induced by retinoic acid treatment at various exposure times. Several genes are induced in Pluripotent mouse P19 embryonal carcinoma cells (P19EC) RA treatment. At least 50 different cDNA fragments corresponding to RA-induced genes were isolated, 6 of them are known proteins, 4 of which are described as RA inducible, while the remaining 40 are unknown and novel genes. Two of these unknown novel genes are Stra1 and Stra6. Stra1 corresponds to the mouse ligand for Cek5 receptor protein tyrosine kinase and Stra6 is a vitamin A transporter (1). Stra6 is a membrane bound protein containing 10 TMD characteristic of solute carrier proteins. Stra6 protein is expressed in various tissues including fibroblasts and eye, a detailed analysis of distinct parts of an adult eye revealed expression in sclera, retina, retinal pigment epithelium and trabecular mashwork but not in choroid and iris (2). A number of mutations in the Stra6 (chromosome 15) gene have been studied. A homozygous deletion generating a premature stop codon that led to absence of the immunoreactive protein in patient fibroblasts culture and three miss-sense mutations (P90L, P293L and T321P) caused significant alteration in the geometry of the loops connecting the transmembrane helices of Stra6. Two other mutations in the C-terminal region caused aberration in the SH2 binding motifs and in the phosphorylation of the Stra67 protein (2). Patients with these mutations show anophthalmia and distinct eyebrows as common signs along with alveolar dysplasia or a common congenital heart defect and diaphragmatic hernia. Stra6 is a 99 kDa membrane bound protein with 10 TMD as commonly seen in all membrane transporter proteins. The Stra6 selective-antibodies were generated against conserved sequences from the mouse and human Stra6 protein that are unique to either mouse or human stra6 protein. MyBioSource employs cyclic peptide methodology for generating antibodies, which results in higher titer and specificity. The Str6-selective antibodies are affinity purified against immobilized antigen based affinity chromatography which yielded epitope-specific antibodies. The Str6 antibodies label a 99kDa protein in Western blot using Western blot positive control for Stra6 (PC-Str6). Anti-Stra6-selective antibodies are most suitable for immunoprecipitation and immunohistochemical localization of Str6 protein. MyBioSource will conjugate antibodies with various fluorescent probes upon request at nominal charge. Limited quantities of antigens are also available for blocking studies. Please enquire for their availability before ordering. MyBioSource also provides antibodies to various eye related proteins and other targets, for a complete listings visit our website at www.mybiosource.com. MyBioSource will also provide Western blot positive controls for most of these antibodies in ready-to-use buffer for easy identification of respective proteins